Should I admit an 83-year-old patient with atrial fibrillation with rapid ventricular response who is already on apixaban (Eliquis)?

Should You Admit This 83-Year-Old Patient with AFib RVR on Eliquis?

Admission is not automatically required solely because the patient has AFib with RVR while on Eliquis—the decision depends on whether you can achieve adequate rate control in the emergency department, the patient's hemodynamic stability, symptom severity, and ability to arrange close outpatient follow-up.

Decision Framework for Admission vs. Discharge

Admit if ANY of the following are present:

• Hemodynamic instability (hypotension, acute heart failure, ongoing chest pain, syncope)
• Tachycardia-induced cardiomyopathy or evidence of new/worsening heart failure 1
• Inability to achieve adequate rate control in the ED with IV or oral agents
• Symptomatic despite rate control attempts (severe dyspnea, chest pain, presyncope)
• Concurrent acute illness requiring hospitalization (infection, ACS, PE, etc.)
• Significant electrolyte abnormalities or other precipitating factors requiring inpatient management
• Concern for medication non-adherence or inability to follow up within 24-48 hours

Consider Discharge if ALL of the following are met:

• Hemodynamically stable with adequate rate control achieved (HR <110 bpm at rest is reasonable target)
• Minimal symptoms or symptoms resolved with rate control
• No evidence of acute precipitant requiring hospitalization
• Confirmed therapeutic anticoagulation (patient taking Eliquis as prescribed—verify dose is appropriate: 5 mg BID or 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5) 2
• Reliable outpatient follow-up within 24-48 hours with cardiology or primary care
• Patient/family understanding of warning signs and when to return

Rate Control Strategy

The 2024 ACC/AHA/ACCP/HRS guidelines provide specific pharmacologic options for rate control 1:

IV options in the ED:

• Metoprolol: 2.5-5 mg IV bolus over 2 minutes, up to 3 doses
• Diltiazem: 0.25 mg/kg IV over 2 minutes (may repeat 0.35 mg/kg), then 5-15 mg/h infusion
• Esmolol: 500 μg/kg bolus, then 50-300 μg/kg/min infusion (ultra-short acting, useful if concerned about tolerance)

Avoid diltiazem/verapamil if heart failure with reduced ejection fraction 1

Oral transition options:

• Metoprolol succinate 50-400 mg daily
• Diltiazem ER 120-360 mg daily (if no HFrEF)
• Consider adding digoxin if beta-blocker/CCB alone insufficient, though onset is slower

Anticoagulation Considerations in This 83-Year-Old

The patient is already appropriately anticoagulated on Eliquis, which is protective:

• Apixaban demonstrates superior safety and effectiveness compared to warfarin in very elderly patients (≥85 years), with lower rates of stroke/systemic embolism (HR 0.75) and major bleeding (HR 0.69) 3
• In Japanese elderly patients ≥85 years on appropriate-dose apixaban, stroke/SE rates were only 1.95 per 100 person-years, with bleeding requiring hospitalization at 2.61 per 100 person-years 4
• Meta-analysis confirms NOACs show superior effectiveness (HR 0.83 for stroke) and safety (HR 0.58 for intracranial hemorrhage) versus warfarin in patients ≥75 years 5

Verify the dose is correct 2:

• 5 mg BID is standard
• 2.5 mg BID if patient has ≥2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL
• Check renal function—adjust if CrCl 15-30 mL/min (though 5 mg or 2.5 mg BID both acceptable per dosing criteria)

Do NOT stop Eliquis—stopping anticoagulation in AFib increases stroke risk significantly 2

Common Pitfalls to Avoid

1. Don't assume RVR = admission automatically—many patients can be rate-controlled and discharged safely with close follow-up
2. Don't stop anticoagulation due to concerns about falls or age—the stroke risk far exceeds bleeding risk in this population, and apixaban has the most favorable risk profile 5, 6
3. Don't underdose Eliquis empirically—off-label dose reduction (when not meeting criteria) is common (17% in one study) but associated with higher mortality without clear benefit 7
4. Don't forget to identify and treat precipitants—infection, dehydration, hyperthyroidism, alcohol, medication non-adherence
5. Don't discharge without concrete follow-up plan—these patients need reassessment within 24-48 hours

Bottom Line Algorithm

AFib RVR in 83yo on Eliquis
         ↓
Unstable/severely symptomatic? → YES → ADMIT
         ↓ NO
Achieve rate control in ED? → NO → ADMIT
         ↓ YES
Precipitant requiring admission? → YES → ADMIT
         ↓ NO
Reliable 24-48h follow-up available? → NO → ADMIT
         ↓ YES
Patient/family understand plan? → NO → ADMIT
         ↓ YES
DISCHARGE with close follow-up

Most importantly: This 83-year-old's anticoagulation with Eliquis is appropriate and protective—the RVR itself is the issue to address, not an indication to change anticoagulation strategy 2, 3, 6.